John Crowley, Amicus CEO (Amicus via YouTube)
Amicus and Perceptive call off SPAC merger for gene therapy spinout after recent setback
Roughly a month after Amicus Therapeutics reported an unexpected setback in a gene therapy planned to be spun out in a SPAC deal, the biotech and its blank check partner have called off the merger — the second high-profile SPAC decoupling in recent months.
Amicus will not spin out its gene therapy unit with Arya Sciences Acquisition IV, the fourth SPAC belonging to Joseph Edelman’s Perceptive, after all. The two say they have mutually agreed to end merger discussions, leaving Edelman with about another year to find a partner to take public.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters